Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cervical Cancer
Data presented on vaccine response in adolescents
June 9th, 2005
Gardasil, Merck & Co., Inc.'s investigational quadrivalent human papillomavirus (HPV) vaccine, produced higher anti-HPV immune responses among adolescent males and females compared to young women, according to new study data. Gardasil is an investigational vaccine designed to prevent infection from four common HPV types - 16, 18, 6, and 11 - and related cervical cancer, cervical precancers, and genital warts. These data from a Phase III study of Gardasil were presented for the first time at the annual meeting of the European Society of Pediatric Infectious Diseases (ESPID). This is the first trial to evaluate the immune responses and tolerability among young adolescents...
Source: Women's Health Weekly (2005-06-09)
|
